Five Prime IPO carries on biotech boom

Five Prime Ther­a­peu­tics Inc.‘s $62 mil­lion stock debut Wednes­day is get­ting good reviews on Wall Street so far, con­tin­u­ing the biotech indus­try’s rise to invest­ment favor.

Five Prime is the fourth Bay Area biotech ini­tial pub­lic offer­ing this year and is one of four nation­al­ly this week, includ­ing Fate Ther­a­peu­tics Inc. of San Diego.

Read the full San Fran­cis­co Busi­ness Times arti­cle here